Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.

Supporting you

We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years. 

Image of the MS-UK Helpline button graphic containing a link to the Helpline page

Image of the New Pathways magazine button graphic containing a link to the New Pathways magazine page


Several studies have shown that bone mineral density (BMD) at the femoral neck decreases with increasing physical handicap in multiple sclerosis (MS) patients. BMD measurements in an unselected...

It has been reported that oestrogen may affect the level of Th-1 / Th-2 lymphocytes and ratio of Th-1 and Th-2 that play an important role in immune pathogenesis in multiple sclerosis (MS)....

The prevalence of trigeminal neuralgia in multiple sclerosis (MS) patients is higher than in the general population. Patients whose pain is insufficiently relieved by medication requires invasive...

Previous studies on caffeine and risk of multiple sclerosis (MS) yielded different results, with one study suggesting a positive effect on disease progression. In this...

Biopharmaceutical company Mapi Pharma will present two-year clinical...

MPs and other policy makers should not let Brexit challenges draw attention and funding away from the chance to improve outcomes for everyone living with MS says Professor David Taylor...

AIMS, the UK’s first charity with a focus on Haematopoietic Stem Cell Transplant (HSCT) for multiple sclerosis (MS) and autoimmune disease, is set to launch...

A 10-year study of four multiple sclerosis (MS) disease modifying therapies (DMTs) -  Avonex, Rebif, Betaferon and Copaxone – has found them to be cost effective and successful at reducing disease...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Gilenya (fingolimod) for the treatment of children and adolescents,...

Pages

Live Chat Software by Click4Assistance UK